MedPath

DongKook Pharmaceutical Co., Ltd.

DongKook Pharmaceutical Co., Ltd. logo
🇰🇷South Korea
Ownership
Public
Established
1992-01-01
Employees
1.1K
Market Cap
-
Website
http://www.dkpharm.co.kr

Clinical Trials

10

Active:1
Completed:7

Trial Phases

4 Phases

Phase 1:4
Phase 3:2
Phase 4:1
+1 more phases

Drug Approvals

13

PHILIPPINES:13

Drug Approvals

Parafol

Approval Date
Jul 14, 2025
PHILIPPINES

Profoly

Approval Date
Jul 14, 2025
PHILIPPINES

None

Approval Date
Jul 14, 2025
PHILIPPINES

Leuprolin

Approval Date
Jul 14, 2025
PHILIPPINES

Novafrol

Approval Date
Jul 14, 2025
PHILIPPINES

Pamisol

Approval Date
Jul 14, 2025
PHILIPPINES

Propolyf

Approval Date
Jul 14, 2025
PHILIPPINES

Pofol

Approval Date
Jul 14, 2025
PHILIPPINES

Goprofol

Approval Date
Jul 14, 2025
PHILIPPINES

Blirelin

Approval Date
Jul 14, 2025
PHILIPPINES
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (40.0%)
Not Applicable
3 (30.0%)
Phase 3
2 (20.0%)
Phase 4
1 (10.0%)

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Phase 3
Recruiting
Conditions
Advanced Prostate Cancer
Interventions
First Posted Date
2024-07-08
Last Posted Date
2024-07-08
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
154
Registration Number
NCT06490328
Locations
🇰🇷

Ewha Womans University mokdong Hospital, Seoul, Korea, Republic of

Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee

Not Applicable
Completed
Conditions
Osteoarthritis of Knee
First Posted Date
2023-09-01
Last Posted Date
2023-09-21
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
250
Registration Number
NCT06021444
Locations
🇰🇷

chung-Ang University Hospital, Seoul, Korea, Republic of

Efficacy and Safety of DKB-119 in Patients in Crow's Feet

Not Applicable
Active, not recruiting
Conditions
Crow's Feet
First Posted Date
2023-09-01
Last Posted Date
2023-09-13
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06021418
Locations
🇰🇷

Chungang-University Hospital, Seoul, Korea, Republic of

Pharmacokinetics and Safety of AmBisome and DKF-5122

Phase 1
Completed
Conditions
Invasive Fungal Infections
Neutropenic Fever
Interventions
First Posted Date
2023-03-01
Last Posted Date
2023-03-01
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
38
Registration Number
NCT05749380
Locations
🇰🇷

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of

Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds

Not Applicable
Completed
Conditions
Nasolabial Folds
First Posted Date
2022-11-10
Last Posted Date
2022-11-14
Lead Sponsor
Dongkook Pharmaceutical Co., Ltd.
Target Recruit Count
82
Registration Number
NCT05612958
Locations
🇰🇷

Chung-Ang University Hospital, Seoul, Korea, Republic of

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.